GEMPHARMATECH CO., LTD. — Investor Relations & Filings
About GEMPHARMATECH CO., LTD.
GemPharmatech Co., Ltd. is a global biotechnology company specializing in the development and distribution of genetically engineered mouse models (GEMMs) for biomedical research. The company maintains one of the world's largest repositories of mouse strains, including knockout (KO), conditional knockout (cKO), and humanized models designed for oncology, immunology, and metabolic disease studies. Through its Knockout All Project, GemPharmatech aims to create KO and cKO strains for all protein-coding genes in the mouse genome. Beyond model production, the company provides comprehensive preclinical services such as efficacy testing, safety assessment, phenotyping, and customized gene editing using CRISPR/Cas9 technology. Serving pharmaceutical enterprises, biotechnology firms, and academic institutions, GemPharmatech supports drug discovery and fundamental life science research with high-throughput production capabilities and specialized germ-free mouse facilities.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 董事会审计委员会对会计师事务所履行监督职责情况报告 | 2026-04-22 | Chinese | |
| 关于使用部分闲置募集资金进行现金管理的公告 | 2026-04-22 | Chinese | |
| 独立董事2025年度述职报告(余波) | 2026-04-22 | Chinese | |
| 关于确认2025年度关联交易及预计2026年度日常关联交易公告 | 2026-04-22 | Chinese | |
| 关于2026年度董事、高级管理人员薪酬方案的公告 | 2026-04-22 | Chinese | |
| 关于2026年度对子公司担保额度预计的公告 | 2026-04-22 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 39537538 | 董事会审计委员会对会计师事务所履行监督职责情况报告 | 2026-04-22 | Chinese | ||
| 39537537 | 关于使用部分闲置募集资金进行现金管理的公告 | 2026-04-22 | Chinese | ||
| 39537536 | 独立董事2025年度述职报告(余波) | 2026-04-22 | Chinese | ||
| 39537535 | 关于确认2025年度关联交易及预计2026年度日常关联交易公告 | 2026-04-22 | Chinese | ||
| 39537531 | 关于2026年度董事、高级管理人员薪酬方案的公告 | 2026-04-22 | Chinese | ||
| 39537529 | 关于2026年度对子公司担保额度预计的公告 | 2026-04-22 | Chinese | ||
| 39537528 | 药康生物2026年一季度报告 | 2026-04-22 | Chinese | ||
| 39537526 | 华泰联合证券有限责任公司关于江苏集萃药康生物科技股份有限公司确认2025年度关联交易的核查意见 | 2026-04-22 | Chinese | ||
| 39537523 | 药康生物2025年度审计报告 | 2026-04-22 | Chinese | ||
| 39537518 | 外汇套期保值业务管理制度 | 2026-04-22 | Chinese | ||
| 39537517 | 2025年度审计委员会履职情况报告 | 2026-04-22 | Chinese | ||
| 39537509 | 关于新增公司部分内部治理制度的公告 | 2026-04-22 | Chinese | ||
| 39537508 | 关于公司2026年度申请银行综合授信额度的公告 | 2026-04-22 | Chinese | ||
| 39537507 | 关于2025年度“提质增效重回报”行动方案评估报告暨2026年度“提质增效重回报”行动方案 | 2026-04-22 | Chinese | ||
| 39537506 | 关于开展外汇套期保值业务的公告 | 2026-04-22 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
GEMPHARMATECH CO., LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58096/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58096 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58096 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58096 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58096}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for GEMPHARMATECH CO., LTD. (id: 58096)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.